Aprea Therapeutics (APRE) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on June 16, 2026, with stockholders able to vote online, by phone, or by mail.

• Six proposals are up for vote, including director elections, auditor ratification, a reverse stock split, executive compensation, say-on-pay frequency, and potential adjournment.

• The Board recommends voting FOR all proposals and provides detailed instructions for participation and voting.

Voting matters and shareholder proposals

• Proposal 1: Elect three Class I directors for three-year terms expiring in 2029.

• Proposal 2: Ratify EisnerAmper LLP as independent auditor for 2026.

• Proposal 3: Approve a reverse stock split at a ratio between 1-for-3 and 1-for-8, at the Board's discretion, to maintain Nasdaq listing.

• Proposal 4: Advisory vote on executive compensation (say-on-pay).

• Proposal 5: Advisory vote on frequency of say-on-pay votes, with Board recommending annual votes.

• Proposal 6: Approve adjournment of the meeting if more time is needed to solicit votes for Proposal 3.

Board of directors and corporate governance

• The Board consists of nine members divided into three classes with staggered three-year terms.

• Eight of nine directors are independent; the CEO is not independent.

• Board committees include Audit, Compensation, Nominating and Corporate Governance, and Research & Development, all with independent members.

• The Board regularly evaluates its effectiveness and conducts self-assessments.

• Board diversity and succession planning are emphasized.